Equities Analysts Offer Predictions for DNTH FY2026 Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Dianthus Therapeutics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will post earnings per share of ($3.44) for the year. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share.

DNTH has been the subject of a number of other research reports. Robert W. Baird cut their price objective on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating for the company in a report on Tuesday, May 13th. Wedbush restated an “outperform” rating and set a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Finally, Guggenheim reiterated a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $53.00.

Dianthus Therapeutics Price Performance

DNTH opened at $18.19 on Tuesday. The firm has a fifty day moving average price of $18.91 and a 200 day moving average price of $21.22. Dianthus Therapeutics has a 1 year low of $13.37 and a 1 year high of $32.27. The stock has a market cap of $584.99 million, a P/E ratio of -7.28 and a beta of 1.36.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.04. The business had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $0.81 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of DNTH. US Bancorp DE raised its position in shares of Dianthus Therapeutics by 2,013.3% during the 1st quarter. US Bancorp DE now owns 1,585 shares of the company’s stock worth $29,000 after purchasing an additional 1,510 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Dianthus Therapeutics during the 4th quarter worth approximately $33,000. KBC Group NV acquired a new position in shares of Dianthus Therapeutics during the fourth quarter valued at approximately $35,000. BNP Paribas Financial Markets purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter worth approximately $59,000. Finally, GAMMA Investing LLC raised its position in shares of Dianthus Therapeutics by 3,030.6% in the first quarter. GAMMA Investing LLC now owns 3,882 shares of the company’s stock valued at $70,000 after buying an additional 3,758 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.